SDI.TO : Summary for SPECTRAL MEDICAL, INC. - Yahoo Finance

U.S. Markets open in 3 hrs 10 mins

Spectral Medical Inc. (SDI.TO)


Toronto - Toronto Delayed Price. Currency in USD
Add to watchlist
0.000.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.00
Open0.00
Volume0
Day's Range0.00 - 0.00
52 Week Range
Avg. VolumeN/A
  • Zacks Small Cap Researchlast year

    EDT.TO: Evidence For Toraymyxin Use Continues To Grow; Spectral Signs Strategic Distribution Agreement In Fifteen Middle And Far East Countries

    On 19 October, 2015 Spectral Medical Inc. (EDT.TO) (EDTXF) filed a report comprised of all available published literature (peer-reviewed articles, observational studies and case reports) reporting the use of Toraymyxin™ (PMX) over a 22 year period from 1993 to September 2015, with the  FDA. Toray Medical Co., Ltd. (TMC) is the distributor for EAA™ (Spectral's rapid test for the assessment of endotoxin activity in human whole blood) in Japan. The press release on October 21, 2015 revealed that Spectral has entered into an exclusive distribution agreement with TMC to market EAA in the Middle and Far East countries comprising of Saudi Arabia, India, South Korea, Taiwan, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Cambodia, Myanmar, Brunei, Laos, and Turkey.

  • Zacks Small Cap Researchlast year

    EDT.TO: Q2 2015 Financial Results, EUPHRATES Update

    Spectral initiated the EUPHRATES Phase 3 clinical trial in June 2010 and had 15 sites up and running by the end of 2012. The EUPHRATES trial is screening approximately 125 patients per week, with most patients not qualifying due to not meeting the vasopressor requirements, not having a MODS score 9, or not having an elevated EAA score. The primary outcome of the EUPHRATES trial is now 28-day all-cause mortality in patients that are in severe septic shock with EAA 0.6 and a MODS score of 9.

  • Zacks Small Cap Research2 years ago

    EDT.TO: Phase 3 Septic Shock Trial Continues At Spectral Medical

    This compares to $4.0 million in operating expenses for the first quarter of 2014, with the decrease due almost entirely to fewer new sites being initiated in the EUPHRATES trial. Spectral management plans to perform that analysis on these amended protocol patients enrolled through the end of the third quarter 2014.